Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levroso Long
- Development stage
- Phase 4
- Lead developer
- NovaMedica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Levroso Long is a fixed-dose combination of diphenhydramine and melatonin developed by NovaMedica for the treatment of insomnia in adults. It is formulated as modified-release capsules containing a combination of immediate-release diphenhydramine (to facilitate sleep initiation) and extended-release melatonin (to maintain sleep quality and duration throughout the night). Diphenhydramine acts as a first-generation antihistamine by antagonizing central histamine H1 receptors, while melatonin acts as an agonist at MT1 and MT2 receptors to regulate the circadian rhythm and sleep-wake cycle. The drug is approved and marketed in Russia.
- Brand names
- Levroso Long
- Other names
- diphenhydramine + melatoninmelatonin + diphenhydramineЛевросо Лонг
02
Targets
HRH1 (Histamine H1 Receptor)MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)
Beyond the preview
Go deeper on Levroso Long.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Levroso Long.